Phase 2 private biotech developing neoantigen targeted personalized therapeutic cancer vaccines (PTCVs) based on proprietary DNA platform. Compared with mRNA-based cancer vaccines currently under development by Merck/Moderna & Roche/BioNTech, DNA platform offers highest neoantigen payload, 100% CD8 + CD4 TIL responses, and, fastest needle-to-needle time to maximize efficacy and utility across all adjuvant & advanced cancer settings. Phase 1b/2a trial in 2L advanced HCC data recently published in Nature Medicine; trial hit statistical significance on ORR endpoint with remarkable safety and tolerability demonstrated. Institutional VC backed company (Santé, INO, KIP-VC, Flerie, 3B Future, SHC) now raising ~$40M Series B to fund Phase 2 RCT in unmethylated GBM on path to registration, while tumor agnostic platform supports seamless pipeline expansion into additional indications.